Omnicell falls after downbeat 2022 earnings view

Omnicell

15/02/2022 18:21

** Shares of healthcare tech firm  OMCL.O  fall 7% to
$137.10 
    ** Co on Monday after market close forecast 2022 adjusted
EBITDA (earnings before interest, taxes, depreciation, and
amortization) between $243 mln and $255 mln, falling short of
Street estimates  urn:newsml:reuters.com:*:nBw1mQ6dta
    ** Co said on conference call it expects supply chain
challenges and inflationary cost impacts to continue throughout
2022
    ** Co's Q4 revenue rose 25% to $311.7 mln, driven by strong
demand for its products and services that help improve
medication adherence
    ** Brokerage Piper Sandler cuts its PT on OMCL to $181 from
$211, but maintains its "overweight" rating, saying co's
challenges are transitory and the guidance related weakness in
shares is a buying opportunity
    ** Stock rose 50% in 2021

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))